Join
Live feed
·
INSIDERFilingvia Quantisnow
BioXcel Therapeutics Inc. logo

CEO and President Mehta Vimal converted options into 49,758 shares and sold $21,108 worth of shares (19,419 units at $1.09) as part of a pre-agreed trading plan, increasing direct ownership by 77% to 69,598 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BTAI (BioXcel Therapeutics Inc.) and more on Quantisnow.